BridgeMD
The use of [68Ga]Ga-FAPI PET/MRI in assessing disease activity in patients with Graves’ orbitopathy
EU CTIS ID: 2025-521163-12-01
What this study is testing
The main objective of this study is to compare the uptake of FAPI (Fibroblast Activation Protein Inhibitor) in patients with active Graves' Ophthalmopathy (GO) versus those with inactive GO. This comparison aims to determine the differential uptake patterns and potential diagnostic value of FAPI in assessing disease activity in GO patients.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Inclusion of 5 patients with Graves Orbitopathy (GO) and Clinical Activity Score (CAS) >3, consistent with active GO.
- Inclusion of 5 patients with GO who have previously undergone CAS >3, but with a current low CAS of 0 or 1 for at least 6 months (i.e. inactive GO)
You likely can't join if
- General exclusion criteria for MRI, including (but not limited to) claustrophobia, metal-splinters in face-area, recent surgery etc.
- For active GO: if PET-MRI can not be performed <14 days, patient will not be included
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.